Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with P53 protein accumulation

Modern Pathology

Volumn 9, Issue 1, 1996, Pages 41-47

  Kallakury, Bhaskar V S ^a   Figge, James ^a   Leibovich, Bradley ^a   Hwang, James ^a   Rifkin, Matthew ^a   Kaufman, Ronald ^a   Figge, Helen L ^a   Nazeer, Tipu ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

bcl 2; Major breakpoint region; p53; Prostatic adenocarcinomas

Indexed keywords

ENDOGENOUS COMPOUND; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SOUTHERN BLOTTING;

ADENOCARCINOMA; BLOTTING, SOUTHERN; GENE REARRANGEMENT; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; STAINING AND LABELING; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030051572     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Reed JC: Cellular mechanisms of bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1, 1994
2. Tsujimoto Y, Cossman J, Jaffe E, Croce C: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440, 1985
3. Seto M, Jaeger U, Hockett RD, et al.: Alternative promoters and exons, somatic mutation and deregulation of the bcl-2-Ig fusion gene in lymphoma. EMBO J 7:123, 1988
4. Bakhshi A, Jensen JP, Goldman P, et al.: Cloning the chromosomal breakpoint of t(14: 18) human lymphomas: Clustering around in on chromosome 14 and near a transcriptional unit on 18. Cell 41:899, 1985
5. Tsujimoto Y, Louie E, Bashir MM, Croce CM: The reciprocal partners of both the t(14: 18) and the t(11:14) translocations involved in B-cell neoplasms are rearranged by the same mechanism. Oncogene 2:347, 1988
6. Cleary ML, Galili N, Sklar J: Detection of a second t(14:18) breakpoint cluster region in human follicular lymphomas. J Exp Med 164:315, 1986
7. Hockenbury D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334, 1990
8. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC: Investigations of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum and outer mitochondrial membranes. Cancer Res 53: 4701, 1993
9. Reed JC, Meister L, Tanaka S, et al.: Differential expression of bcl-2 proto-oncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 51:6529, 1991
10. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88:6961, 1991
11. Leek RD, Kaklamanis L, Pezella F, Gatter KC, Harris AL: Bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumors and in-situ cancer. Br J Cancer 69:135, 1994
12. Lu OL, Elia G, Lucas S, Thomas JA: Bcl-2 proto-oncogene expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. Int J Cancer 53:29, 1993
13. Yonish-Ronach E, Resnitzky D, Lotem J, Sachs L, Kim-Chi A, Oren A: Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345, 1991
14. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wild type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A 89:4495, 1992
15. Haldar S, Negrini M, Sabbioni S, Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Can Res 54:2095, 1994
16. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J, et al.: Expression of the proto-oncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Can Res 52:6940, 1992
17. Segal NH, Cohen RJ, Haffejee Z, Savage N: Bcl-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 118:616, 1994
18. Gleason D: Histologic grading and clinical staging of carcinoma of the prostate. In Urologic Pathology: The Prostate; edited by Tannenbaum M, p 171. Philadelphia, Lea & Febiger, 1977
19. Gleason DF, Mellinger GT: Veterans Administration Cooperative Urologic Research Group 1974. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 11: 58, 1974
20. Kallakury BVS, Figge JJ, Ross JS, Fisher HAG, Figge HL, Jennings TA: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Human Pathol 25:92, 1994
21. Kallakury BVS, Jennings TA, Ross JS, et al.: Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high grade prostatic adenocarcinoma. Diagn Mol Pathol 3:227, 1994
22. Ambros RA, Vigna PA, Figge J, et al.: Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 73:1686, 1994
23. Westra WH, Offerhaus GJA, Goodman SN, et al.: Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinoma is associated with cigarette smoking. Am J Surg Pathol 17:213, 1993
24. Sambrook J, Fritsch EF, Manaitis T: Analysis and cloning of eukaryotic genomic DNA in molecular cloning. In A Laboratory Manual, edited by Nolan C, p 9.16. Cold Spring Harbor Laboratory Press, 1989
25. Sambrook J, Fritsch EF, Maniatis T: Analysis of genomic DNA by Southern hybridization in molecular cloning. In A Laboratory Manual, edited by Nolan C, p 9.31. Cold Spring Harbor Laboratory Press, 1989
26. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML: Expressions in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14:18) chromosomal translocation. N Engl J Med 318:1638, 1988
27. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A: Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 307:1231, 1982
28. Limpens J, DeJong D, VanKrieken JHJM, et al.: Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 6:2271, 1991
29. Pezzella F, Tse AGD, Cosdell JL, Pulford KAF, Katter KC, Mason DY: Expression of bcl-2 oncogene protein is not specific for the 14:18 chromosomal translocation. Am J Pathol 137:225, 1990
30. Zutter M, Hockenbury D, Silverman GA, Korsemeyer SJ: Immunolocalization of the bcl-2 protein within hematopoietic neoplasms. Blood 78:1062, 1991
31. Pezzella F, Turley H, Kuzu I, et al.: Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 329:690, 1993
32. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C: Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 145:294, 1994
33. Chandler D, El-Naggar AK, Brisbay S, Redline RW, McDonnell TJ: Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: Evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol 25:789, 1994
34. Daidone MG, Veneroni S, Benini SM, et al.: Expression of bcl-2 provides prognostic information in node-negative breast cancers (abstract). Proc Am Assoc Cancer Res 34:28, 1993
35. Bronner M, Culin C, Reed J, Furth E: Bcl-2 proto-oncogene and the gastrointestinal mucosal epithelial progression model as related to proposed morphologic and molecular oncogenetic sequences (abstract). Lab Invest 68:43A, 1993
36. Zhan QFC, Fornale AJ Jr: Induction of cellular p53 antibody by DNA-damaging agents and growth arrest. Mol Cell Biol 13: 4242, 1993
37. Pezzella F, Morrison H, Jones M, et al.: Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 22:39, 1993